Rick Schnellman
Oprichter bij Rediscovery Life Sciences LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Richard J. Shea | M | - |
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | - |
Michael Voevodsky | M | 59 |
Mitochem Therapeutics, Inc.
Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | - |
Patrick K. Donnelly | M | - |
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | - |
Bärbel Rohrer | M | - |
Mitochem Therapeutics, Inc.
Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | - |
David Adair | M | - |
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | - |
Sunil Desai | M | - |
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | - |
Anita Watkins | F | - |
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | 4 jaar |
Gyda Caren Beeson | M | - |
Mitochem Therapeutics, Inc.
Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 8 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Rick Schnellman
- Persoonlijk netwerk